Board Appointment

RNS Number : 6575C

Ergomed plc

18 June 2019

 

Board appointment

Appointment of Richard Barfield as an Executive Director to the Board of Ergomed plc

Guildford, UK - 18 June 2019: further to the Company's announcement on 4 June 2019, Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company") today announces that Richard Barfield, its Chief Financial Officer, is appointed to the board as an Executive Director with immediate effect. Stuart Jackson, former Chief Financial Officer of the Company, has resigned from the Board of the Company with immediate effect but will continue to be employed by the Company until early July.

Since qualifying as a chartered accountant, Richard has more than 25 years' experience at Chief Financial Officer level in the healthcare, technology and business services sectors in US multinational companies as well as in UK-listed and PE-backed businesses. His expertise includes turnarounds, fundraisings, acquisitions and disposals, and he has extensive international experience. Richard has also held roles as Chief Executive Officer, Chairman, and Audit Committee Chairman of UK-listed companies as well as serving as a Board Member of a world-leading teaching hospital. 

Richard has proven experience within the contract research sector having most recently been Chief Financial Officer at Chiltern International Ltd from July 2013 to March 2018, which was a leading global mid-tier private CRO. During his five years at Chiltern, Richard was instrumental in transforming the corporate finance and strategy of the business, enabling it to grow revenues from $160m to $550m. The eventual sale of Chiltern to Covance, a division of the US-listed healthcare company Laboratory Corporation of America Holdings (LabCorp), in late 2017 for $1.2bn delivered a cash return of over 4x to investors in Chiltern's December 2013 refinancing.

Save as disclosed below, in relation to current and prior directorships, Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Richard Barfield's appointment.

Mr Richard Timothy Barfield, aged 61, currently holds and has held the following directorships in the past five years:

Current directorships:

RDB NOTO

Directorships in the past five years:

Chiltern Clinical Research (Philippines) Inc. Chiltern Clinical Research KK Chiltern Clinical Research S.R.L. Chiltern Clinical Research YH Chiltern International (Canada) Ltd. Chiltern International (Hong Kong) Ltd. Chiltern International AB Chiltern International B.V. Chiltern International BVBA/Sprl Chiltern International EOOD Chiltern International GmbH CHILTERN INTERNATIONAL GROUP LIMITED CHILTERN INTERNATIONAL HOLDINGS LIMITED Chiltern International Inc. Chiltern International Kft CHILTERN INTERNATIONAL LIMITED(1) Chiltern International Ltd.(2) Chiltern International Portugal Lda Chiltern International Pte Ltd Chiltern International Pty. Ltd. Chiltern International Pvt. Ltd. Chiltern International SARL Chiltern International SP Zoo Chiltern International Spain SA Chiltern International SRL(3) Chiltern International SRL(4) Chiltern International sro Chiltern International Switzerland SARL Chiltern International Taiwan Ltd. Chiltern Klinik Arastirma Organizayson Limited Sirketi Chiltern Pharmaceutical and Technology Consulting (Shanghai) Co. Ltd. Chiltern Research International (Singapore) Ltd. Chiltern Research International Pty. Ltd. Covance Clinical Development GmbH ENDPOINT CLINICAL (UK) LTD Endpoint Clinical India Private Limited Endpoint Clinical, Inc. HAVENFERN LIMITED Integrated Development Associates Co., Ltd. OCKHAM DEVELOPMENT GROUP (HOLDINGS) UK LIMITED Ockham Development Group Inc. OCKHAM EUROPE LIMITED Ockham India Clinical Research and Data Services Pvt. Ltd. Ockham Oncology AB Ockham Oncology GmbH  Ockham Oncology Kft Ockham Oncology Pty. Ltd. Ockham Oncology S.L.U. Ockham Oncology SPRL (Belgium) Pacific Clinical Research India Limited TCR International B.V. TCR Latin America B.V. Theorem Clinical Research Holdings B.V. Theorem Clinical Research Holdings Inc. Theorem Clinical Research Inc. Theorem Clinical Research Kft THEOREM CLINICAL RESEARCH LIMITED Theorem Clinical Research Pte. Ltd.(5) Theorem Clinical Research Pte. Ltd.(6) Theorem Clinical Research Pty Ltd Theorem Clinical Research SARL Theorem Clinical Research SRL Theorem Clinical Research sro Theorem CR Inc. Theorem Foreign Representation Company Theorem Research Associates, Inc.

Notes on duplicate directorship disclosures:

(1)  Note: entity registered in the UK.

(2) Note: entity registered in Israel.

(3) Note: entity registered in Argentina.

(4) Note: entity registered in Italy.

(5) Note: entity registered in Singapore.

(6) Note: Philippines branch office of entity registered in Singapore.

Mr Barfield holds 100,000 ordinary shares of 1p each in the Company, representing 0.21% of the Company's issued share capital.

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser) James Black (Corporate Broking)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott Matthew Neal / Olivia Manser	[e-mail]
MC Services - for Continental European enquiries Anne Hennecke	Tel: [phone]

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 

END

 

 

BOAEALKPFEFNEFF